Company news

GlycoNex, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

GlycoNex Doses First Patient in Phase I Trial of GNX1021, Advancing Its Glycan-Directed ADC into Clinical Development

August 2, 2026

GlycoNex Receives PMDA Approval in Japan to Initiate First-in-Human Phase 1 Trial of GNX1021 in Gastrointestinal Cancers

April 14, 2026

GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADC

March 23, 2026

GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program

December 8, 2025

GlycoNex and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer

November 24, 2025

GlycoNex Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis

October 29, 2025

GlycoNex Abstract on Glycan-Directed ADC GNX1021 Accepted for Presentation at AACR-NCI-EORTC 2025

October 20, 2025

GlycoNex to Participate in BIO Asia-Taiwan 2025

July 21, 2025

Decks